Cochrane · systematic review · CD004143
Long‐term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J, Farquhar, C, Roberts, H, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 14 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCombined continuous hormone therapy (HT) compared with placebo for postmenopausal women
Population: relatively healthy postmenopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Coronary events (MI or cardiac death) Combined continuous hormone therapy (HT) vs placebo | RR 1.89 [1.15, 3.1] | 2 studies · 20993 participants | Moderate Downgraded: indirectness |
Stroke Combined continuous hormone therapy (HT) vs placebo | RR 146 [1.02, 2.09] | 2 studies · 17585 participants | Moderate Downgraded: indirectness |
Venous thromboembolism (DVT or PE) Combined continuous hormone therapy (HT) vs placebo | RR 4.28 [2.49, 7.34] | 2 studies · 20993 participants | Moderate Downgraded: indirectness |
Breast cancer Combined continuous hormone therapy (HT) vs placebo | RR 1.27 [1.03, 1.56] | 1 study · 16608 participants | Moderate Downgraded: indirectness |
Death from lung cancer Combined continuous hormone therapy (HT) vs placebo | RR 1.74 [1.18, 2.55] | 1 study · 16608 participants | Moderate Downgraded: indirectness |
Gallbladder disease Combined continuous hormone therapy (HT) vs placebo | RR 1.64 [1.3, 2.06] | 1 study · 14203 participants | Moderate Downgraded: indirectness |
All clinical fractures Combined continuous hormone therapy (HT) vs placebo | RR 0.78 [0.71, 0.86] | 1 study · 16608 participants | Moderate Downgraded: indirectness |
Oestrogen‐only hormone therapy (HT) compared with placebo for postmenopausal women
Population: relatively healthy postmenopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Coronary events (MI or cardiac death) Oestrogen‐only hormone therapy (HT) vs placebo | RR 0.94 [0.78, 1.13] | 1 study · 10739 participants | Moderate Downgraded: indirectness |
Stroke Oestrogen‐only hormone therapy (HT) vs placebo | RR 1.33 [1.06, 1.67] | 1 study · 10739 participants | Moderate Downgraded: indirectness |
Venous thromboembolism (DVT or PE) Oestrogen‐only hormone therapy (HT) vs placebo | RR 2.22 [1.12, 4.39] | 1 study · 10739 participants | Moderate Downgraded: indirectness |
Venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) Oestrogen‐only hormone therapy (HT) vs placebo | RR 1.32 [1, 1.74] | 1 study · 10739 participants | Moderate Downgraded: indirectness |
Breast cancer Oestrogen‐only hormone therapy (HT) vs placebo | RR 0.79 [0.61, 1.01] | 1 study · 10739 participants | Moderate Downgraded: indirectness |
Gallbladder disease Oestrogen‐only hormone therapy (HT) vs placebo | RR 1.78 [1.42, 2.24] | 1 study · 8376 participants | Moderate Downgraded: indirectness |
All clinical fractures Oestrogen‐only hormone therapy (HT) vs placebo | RR 0.73 [0.65, 0.8] | 1 study · 10739 participants | Moderate Downgraded: indirectness |
Oestrogen‐only hormone therapy (HT) compared to placebo for postmenopausal women
Population: Postmenopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Coronary events (MI or cardiac death) Oestrogen‐only hormone therapy (HT) vs placebo | RR 0.94 [0.78, 1.13] | 1 study · 10739 participants | Moderate |
Stroke Oestrogen‐only hormone therapy (HT) vs placebo | RR 1.34 [1.07, 1.68] | 1 study · 10739 participants | Moderate |
Venous thrombo‐embolism (DVT or PE): CEE 0.625 mg (moderate dose) Oestrogen‐only hormone therapy (HT) vs placebo | RR 1.32 [1, 1.74] | 1 study · 10739 participants | Moderate |
Breast cancer Oestrogen‐only hormone therapy (HT) vs placebo | RR 0.79 [0.61, 1.01] | 1 study · 10739 participants | Moderate |
All clinical fractures Oestrogen‐only hormone therapy (HT) vs placebo | RR 0.73 [0.65, 0.8] | 1 study · 10739 participants | Moderate |
Combined continuous hormone therapy (HT) compared to placebo for postmenopausal women
Population: Postmenopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Coronary events (MI or cardiac death) Combined continuous hormone therapy (HT) vs placebo | RR 1.89 [1.15, 3.1] | 2 studies · 20993 participants | Moderate |
Coronary events (MI or cardiac death) Combined continuous hormone therapy (HT) vs placebo | OR 1.22 [0.98, 1.52] | 1 study · 16608 participants | Moderate |
Stroke Combined continuous hormone therapy (HT) vs placebo | RR 1.38 [1.08, 1.75] | 1 study · 16608 participants | Moderate |
Venous thrombo‐embolism (DVT or PE) Combined continuous hormone therapy (HT) vs placebo | RR 4.28 [2.49, 7.34] | 2 studies · 20993 participants | Moderate |
Breast cancer: Combined continuous HT (moderate dose oestrogen) ‐ CEE 0.625 mg + MPA 2.5 mg for mean 5.6 yrs Combined continuous hormone therapy (HT) vs placebo | RR 1.26 [1.02, 1.56] | 1 study · 16608 participants | Moderate |
All clinical fractures: Combined continuous HT (moderate dose oestrogen) ‐ CEE 0.625 mg + MPA 2.5 mg for median 5.6 yrs Combined continuous hormone therapy (HT) vs placebo | RR 0.78 [0.71, 0.85] | 1 study · 16608 participants | Moderate |